1 Table of Contents 1 Table of Contents 4 1.1 List of Tables 7 1.2 List of Figures 7 2 Introduction 9 2.1 Disease Introduction 9 2.2 Epidemiology 10 2.3 Symptoms 11 2.4 Etiology and Pathophysiology 11 2.5 Diagnosis 13 2.5.1 Office or Clinic Blood Pressure Monitoring 14 2.5.2 Automated Office Blood Pressure Measurement 14 2.5.3 Ambulatory Blood Pressure Monitoring 15 2.5.4 Home Blood Pressure Monitoring 15 2.5.5 Miscellaneous Methods 15 2.5.6 Diagnosis of Target Organ Damage 15 2.5.7 Diagnosis of Hypertension in Pregnancy 15 2.6 Prognosis 16 2.7 Disease Stage 17 2.8 Treatment Options 17 2.8.1 Treatment Algorithm 17 2.8.2 Pharmacological Treatment 18 2.8.3 Non-pharmacological Treatment 22 3 Marketed Products 24 3.1 Angiotensin II Receptor Antagonists 24 3.1.1 Losartan - Merck & Co 24 3.1.2 Olmesartan - Daiichi Sankyo 26 3.1.3 Olmesartan + Amlodipine + Hydrochlorothiazide - Daiichi Sankyo 27 3.1.4 Valsartan - Novartis 28 3.1.5 Telmisartan - Boehringer Ingelheim 29 3.1.6 Azilsartan Medoxomil - Takeda 30 3.2 Calcium Channel Blockers 31 3.2.1 Amlodipine - Pfizer 31 3.3 Renin Inhibitors 32 3.3.1 Aliskiren - Novartis 32 3.4 Angiotensin Converting Enzyme Inhibitors 33 3.4.1 Ramipril - Sanofi 33 3.5 Beta Blockers 33 3.5.1 Carvedilol - GlaxoSmithKline 33 3.6 Multiple Drug Class Combinations 34 3.6.1 Perindopril Arginine + Amlodipine Besylate - Les Laboratoires Servier 34 3.6.2 Amlodipine + Valsartan - Novartis 35 3.7 Comparative Efficacy and Safety of Marketed Products 36 4 Pipeline Analysis 38 4.1 Overview 38 4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 39 4.3 Pipeline by Molecular Target 41 4.4 Promising Pipeline Candidates 43 4.4.1 CS-3150 43 5 Clinical Trial Analysis 45 5.1 Failure Rate 45 5.1.1 Overall Failure Rate 45 5.1.2 Failure Rate by Phase and Molecule Type 46 5.1.3 Failure Rate by Phase and Molecular Target 47 5.2 Clinical Trial Duration 48 5.2.1 Clinical Trial Duration by Molecule Type 48 5.2.2 Clinical Trial Duration by Molecular Target 49 5.3 Clinical Trial Size 50 5.3.1 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development 50 5.3.2 Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development 52 5.4 Competitive Clinical Trials Metrics Analysis 54 6 Multi-Scenario Forecast 56 6.1.1 Geographical Markets 56 6.1.2 Asia-Pacific Market 56 6.2 India 59 6.2.1 Treatment Use Patterns 59 6.2.2 Annual Cost of Therapy 60 6.2.3 Market Size 60 6.3 China 61 6.3.1 Treatment Use Patterns 61 6.3.2 Annual Cost of Therapy 62 6.3.3 Market Size 63 6.4 Australia 64 6.4.1 Treatment Use Patterns 64 6.4.2 Annual Cost of Therapy 65 6.4.3 Market Size 66 6.5 South Korea 67 6.5.1 Treatment Usage Patterns 67 6.5.2 Annual Cost of Therapy 69 6.5.3 Market Size 70 6.6 Japan 70 6.6.1 Treatment Use Patterns 70 6.6.2 Annual Cost of Therapy 71 6.6.3 Market Size 72 7 Drivers and Barriers 74 7.1 Drivers 74 7.1.1 Increasing Aging Populations to Increase Prevalence 74 7.1.2 Increasing Overweight and Obese Population 74 7.1.3 Increase in Daily Sodium Intake 74 7.1.4 Sedentary Lifestyle or Less Physical Activity 75 7.1.5 High Prevalence of Smoking and Alcoholism 75 7.1.6 Diversified Healthcare Reform to Boost Market Growth 76 7.2 Barriers 76 7.2.1 Weak Pipeline and Widespread Usage of Generic Drugs 76 7.2.2 Non-pharmacological First-Line Treatment 76 7.2.3 Lack of Awareness of the Disease Condition 76 8 Deals and Strategic Consolidations 77 8.1 Licensing Deals 77 8.1.1 Deals by Region and Value 77 8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 78 8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 79 8.1.4 Key Licensing Deals 81 8.2 Co-development Deals 82 8.2.1 Deals by Region and Value 83 8.2.2 Deal Value by Stage of Development, Molecule Type, and Molecular Target 84 8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 84 8.2.4 Key Co-development Deals 85 9 Appendix 87 9.1 All Pipeline Drugs by Stage of Development 87 9.1.1 Discovery 87 9.1.2 Preclinical 87 9.1.3 Investigational New Drug/ Clinical Trial Authorization-Filed 89 9.1.4 Phase I 90 9.1.5 Phase II 91 9.1.6 Phase III 91 9.1.7 Pre-registration 93 9.2 Market Forecasts to 2022 93 9.2.1 Asia-Pacific 93 9.2.2 India 94 9.2.3 China 94 9.2.4 Australia 95 9.2.5 South Korea 95 9.2.6 Japan 96 9.3 Reference 96 9.4 Abbreviations 105 9.5 Research Methodology 107 9.5.1 Secondary Research 107 9.5.2 Marketed Product Profiles 107 9.5.3 Late-Stage Pipeline Candidates 107 9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 108 9.5.5 Product Competitiveness Framework 108 9.5.6 Pipeline Analysis 108 9.5.7 Forecasting Model 109 9.5.8 Deals Data Analysis 110 9.6 Contact Us 110 9.7 Disclaimer 110

1.2 List of Figures Figure 1: Anti-hypertensive Therapeutics, Global, Hypertension Prevalence Rate (%), 2009-2012 10 Figure 2: Anti-hypertensive Therapeutics, Physiological Mechanism of Renin-Angiotensin-Aldosterone System 13 Figure 3: Anti-hypertensive Therapeutics: Blood Pressure Measurements and Examination of a Patient to Detect Hypertension 16 Figure 4: Anti-hypertensive Therapeutics, Treatment Algorithm of Hypertension 18 Figure 5: Anti-hypertensive Therapeutics, Combination Therapy Strategies for Blood Pressure Reduction 21 Figure 6: Anti-hypertensive Market, Comparative Efficacy and Safety Heatmap for Marketed Products for the Treatment of Hypertension 37 Figure 7: Anti-hypertensive Market, Comparative Efficacy and Safety Heatmap for Marketed Products for Pediatrics for the Treatment of Hypertension 37 Figure 8: Anti-hypertensive Therapeutics Market, Global, Pipeline, 2016 40 Figure 9: Anti-hypertensive Therapeutics Market, Global, Pipeline by Molecular Target, 2016 42 Figure 10: Anti-hypertensive Therapeutics, Global, Pipeline by Molecular Target and Stage of Development, 2016 43 Figure 11: Anti-hypertensive Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2016 46 Figure 12: Anti-hypertensive Therapeutics, Global, Clinical Trial Failure Rate by Molecule Type (%), 2006-2015 47 Figure 13: Anti-hypertensive Therapeutics, Global, Clinical Trial Failure Rate by Molecular Target (%), 2006-2015 48 Figure 14: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Product by Stage of Development and Molecule Type, 2006-2015 49 Figure 15: Anti-hypertensive Therapeutics, Global, Clinical Trial Duration by Molecular Target, 2006-2015 50 Figure 16: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Trial by Molecular Type, 2006-2015 51 Figure 17: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target, 2006-2015 52 Figure 18: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Product by Molecule Type, 2006-2015 53 Figure 19: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Product by Molecular Target, 2006-2015 54 Figure 20: Anti-hypertensive Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type 55 Figure 21: Anti-hypertensive Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 55 Figure 22: Anti-hypertensive Therapeutics Market, Asia-Pacific, Treatment Patterns (million) and Market Size ($bn), 2015-2022 58 Figure 23: Anti-hypertensive Therapeutics Market, India, Treatment Patterns (million), 2015-2022 59 Figure 24: Anti-hypertensive Therapeutics Market, India, Annual Cost of Therapy ($), 2015-2022 60 Figure 25: Anti-hypertensive Therapeutics Market, India, Market Size ($bn), 2015-2022 61 Figure 26: Anti-hypertensive Therapeutics Market, China, Treatment Patterns (million), 2015-2022 62 Figure 27: Anti-hypertensive Therapeutics Market, China, Annual Cost of Therapy ($), 2015-2022 63 Figure 28: Anti-hypertensive Therapeutics Market, China, Market Size ($bn), 2015-2022 64 Figure 29: Anti-hypertensive Therapeutics Market, Australia, Treatment Patterns (million), 2015-2022 65 Figure 30: Anti-hypertensive Therapeutics Market, Australia, Annual Cost of Therapy ($), 2015-2022 66 Figure 31: Anti-hypertensive Therapeutics Market, Australia, Market Size ($bn), 2015-2022 67 Figure 32: Anti-hypertensive Therapeutics Market, South Korea, Treatment Patterns (million), 2015-2022 68 Figure 33: Anti-hypertensive Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2015-2022 69 Figure 34: Anti-hypertensive Therapeutics Market, South Korea, Market Size ($bn), 2015-2022 70 Figure 35: Anti-hypertensive Therapeutics Market, Japan, Treatment Patterns (million), 2015-2022 71 Figure 36: Anti-hypertensive Therapeutics Market, Japan, Annual Cost of Therapy ($), 2015-2022 72 Figure 37: Anti-hypertensive Therapeutics Market, Japan, Market Size ($bn), 2015-2022 73 Figure 38: Anti-hypertensive Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2016 78 Figure 39: Anti-hypertensive Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2016 79 Figure 40: Anti-hypertensive Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2016 80 Figure 41: Anti-hypertensive Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006-2016 80 Figure 42: Anti-hypertensive Therapeutics Market, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2006-2016 81 Figure 43: Anti-hypertensive Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2006-2016 83 Figure 44: Anti-hypertensive Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2016 84 Figure 45: Anti-hypertensive Therapeutics, Global, Co-development Deals by Phase and Mechanism of Action, 2006-2016 85